Inactive Instrument

Ibex Technologies Stock

Equities

IBT

CA4489375085

Dynamic Chart
IBEX Completes C$37.9-Million Sale Of the Company MT
BBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. from Milfam LLC, McLean Capital Inc., Paul Baehr and others. CI
IBEX Shareholders Approve the C$37.9-Million Sale of Company MT
Refile: IBEX Reports Results For The Second Quarter And Six Months Ending Jan. 31, 2024 MT
IBEX Reports Results For The Second Quarter And Six Months Ending Jan. 31, 2024 MT
IBEX Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI
IBEX Reports Results For The Second Quarter And Six Months Ending January 31, 2024 MT
IBEX Technologies Issues Management Circular Ahead of Vote of C$37.9-Million Acquisition Offer MT
IBEX Technologies Signs Definitive Agreement to Sell Company for $1.45 Cash Per Share MT
15720273 Canada Inc. entered into a binding acquisition agreement to acquire IBEX Technologies Inc. from Milfam LLC, McLean Capital Inc., Paul Baehr and others for CAD 35.5 million. CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on August 2, 2022. CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on July 17, 2023. CI
IBEX Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023 CI
IBEX Technologies Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on August 2, 2022. CI
More news
Managers TitleAgeSince
Chief Executive Officer - 94-12-31
Director of Finance/CFO - 20-11-05
Chief Operating Officer - 18-09-16
Members of the board TitleAgeSince
Director/Board Member 78 99-12-31
Chief Executive Officer - 94-12-31
Director/Board Member - 21-06-15
More insiders
IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.’s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISA’s) for pre-clinical research. The Company has developed a proprietary expression for the production of its enzymes in Flavobacterium heparinum. This expression system allows for producing each glycosaminoglycan (GAG) enzyme separately from other enzymes therefore achieving the highest purity using a well-defined proprietary purification scheme. The Company operates in one industry segment: the production and sale of diagnostic products.
Sector
-
More about the company